A2 Bio­ther­a­peu­tics has raised $80 mil­lion to run three ex­per­i­men­tal CAR-T pro­grams for sol­id tu­mor can­cers. The ...

Biopharma leaders head to San Francisco's JP Morgan Healthcare Conference amid hopes for M&A deals after slow 2024, which saw ...

Versant Ventures' latest biotech emerged on Thursday morning with a $62 million Series A from Bristol Myers Squibb, AbbVie ...

A Dutch biotech cre­at­ing nasal sprays to pro­tect against the flu and coro­n­avirus has raised an ad­di­tion­al $70 ...

Novo Holdings co-leads €32M Series A for Coave Therapeutics, which is developing gene therapies with its ALIGATER technology.

H1 acquires Ribbon Health to expand doctor-patient connections. Ribbon serves about 25M patients yearly; H1 aims to reach ...

Lon­za’s Synaf­fix has se­cured two sep­a­rate li­cens­ing deals with Boehringer In­gel­heim and Japan­ese drug­mak­er ...

RheumaGen raises $15M Series A for HLA gene editing in autoimmune diseases, while RyboDyn gets $4M pre-seed to study non-coding DNA for cancer immunotherapies ...

French biotech MaaT Pharma says its acute graft-versus-host disease treatment exceeded expectations in a single-arm Phase 3 ...

Baby with genetic OTC deficiency shows promising response to iECURE's first-in-kind gene therapy, potentially avoiding liver ...

Revance Therapeutics said Wednesday it will have talks with Teoxane on its bid to take over Revance's company. But Crown ...

Astellas has ended work on a cell therapy that it was exploring for CD20-positive B cell lymphomas, the Japan-based pharma ...